Sulphonylureas and cancer: a case–control study
- 10 December 2008
- journal article
- Published by Springer Science and Business Media LLC in Acta Diabetologica
- Vol. 46 (4), 279-284
- https://doi.org/10.1007/s00592-008-0083-2
Abstract
This study was aimed at the assessment of incidence of malignancies in type 2 diabetic patients treated with different sulphonylureas. A matched case–control study was performed. Cases were 195 diabetic patients aged 69.0 ± 9.2 years who had an incident malignancy. Controls were 195 diabetic patients, unaffected by cancer, who were matched with the corresponding case for age, sex, duration of diabetes, BMI, HbA1c, comorbidity, smoking and alcohol abuse. Exposure to hypoglycaemic drugs during the 10 years preceding the event (or matching index date) was assessed. After adjusting for concomitant therapies, exposure to metformin and gliclazide for more than 36 months was associated with a significant reduction in the risk of cancer (adj. ORs with 95% CI: 0.28 (0.13–0.57), p < 0.001, and 0.40 (0.21–0.57), p = 0.004, respectively). Conversely, use of glibenclamide for at least 36 months was associated with increased incidence of malignancies (adj. OR 2.62 (1.26–5.42); p = 0.009). Treatment with insulin, thiazolidinediones, or acarbose, was not associated with significant differences in the incidence of cancer. Long-term treatments with individual sulphonylureas could have differential effects on the risk of cancer. In particular, the possible protective effect of gliclazide, as well as the risk associated with glibenclamide, deserves further investigation.Keywords
This publication has 17 references indexed in Scilit:
- Rosiglitazone and Risk of CancerDiabetes Care, 2008
- Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemBMC Medicine, 2007
- Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortalityDiabetes/Metabolism Research and Reviews, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cellsChemico-Biological Interactions, 2006
- Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metforminDiabetes/Metabolism Research and Reviews, 2006
- All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanidesDiabetes/Metabolism Research and Reviews, 2003
- 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of HypertensionClinical and Experimental Hypertension, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994